Using streptozotocin (40 mg/kg for 5 consecutive days) treated DBA/2J mice, Zhang et al. [66] demonstrated that FLL-WF inhibited hypercalciuria and improved trabecular bone microstructures by increasing serum levels of PTH and fibroblast growth factor-23 (FGF-23), and upregulating mRNA expression of TRPV6 and CaBP-9k in the duodenum as well as decreasing mRNA and protein expression of calcium-sensing receptor (CaSR) in the kidney of diabetic mice. Here, FGF23 is linked to Hypercalciuria.